VIDEO: CP101 increased microbiome diversity, reduced recurrent C. difficile

VIDEO: CP101 increased microbiome diversity, reduced recurrent C. difficile

In this video, Jessica R. Allegretti, MD, MPH, discussed findings from the PRISM3 trial evaluating an investigational therapeutic for the prevention of recurrent Clostridioides difficile infection.Allegretti, director of the fecal microbiota center at Brigham and Women’s Hospital, presented the trial findings at the ACG Annual Meeting.In the phase 2 PRISM3 trial, patients with recurrent C. difficile were randomly assigned CP101 (Finch Therapeutics), an orally administered investigational microbiome therapeutic, or placebo. Results showed that CP101 met its primary efficacy endpoint ofRead More

Share on facebook
Share on twitter
Share on linkedin